20 Jul Kiji Therapeutics

Posted at 14:33h in by Brittany Miller

Miguel Forte, M.D., Ph.D., President and CEO

Oct. 11 | 1:45pm | Rentschler ATMP Ballroom

Paris, France

(Private)

Kiji Therapeutics has been incorporated in France and Spain in 2023 and is developing engineered off-the-shelf allogeneic cell therapies for multiple indications. The first asset, MSC engineered with CXCR4/IL10, targets autoimmune diseases and is planned to be in the clinic by the second half of 2024. Kiji’s platform will use different cell sources, donor and iPSC derived together with multiple gene engineering approaches to achieve improved therapeutic benefits.

www.kiji-tx.com

About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 7-9, 2024
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions